Y-mAbs Therapeutics, Inc is a clinical biopharmaceutical company based in New York, NY, specializing in the development and commercialization of antibody-based therapeutic products for the treatment of cancer. With a focus on addressing unmet medical needs in both pediatric and adult populations, Y-mAbs aims to become a global leader in the field of oncology. Through partnerships and collaborations, the company is dedicated to changing the course of cancer care and improving patient outcomes.
Y-mAbs Therapeutics has a diverse and advanced product pipeline, including pivotal-stage candidates targeting various cancer types such as neuroblastoma, central nervous system leptomeningeal metastases, osteosarcoma, diffuse intrinsic pontine glioma, and medulloblastoma. The company's research and development efforts are centered around innovative platforms, including immunotherapy, radioimmunotherapy, and companion diagnostics. Founded by a father whose daughter survived high-risk neuroblastoma, Y-mAbs is committed to providing support to patients and their families, while continuously striving to develop effective antibody immunotherapies through ongoing clinical trials.
Generated from the website